TABLE 2.
Demographic and Clinical Characteristics at Time‐of‐Treatment Withdrawal Between Patients With and Without HBsAg Loss
| Demographics | HBsAg‐Negative, n = 6 | HBsAg‐Positive, n = 9 | P Value |
|---|---|---|---|
| Age (years) | 45 (38‐59) | 45 (29‐64) | 0.72 |
| Male gender (%) | 6 (100) | 7 (78) | 0.49 |
| Race (%) | 1.00 | ||
| Caucasian | 1 (17) | 2 (22) | |
| Asian | 5 (83) | 6 (67) | |
| African American | 0 (0) | 1 (11) | |
| GT | 0.54 | ||
| A | 2 (33) | 2 (22) | |
| B | 1 (17) | 0 (0) | |
| C | 1 (17) | 5 (56) | |
| D | 1 (17) | 1 (11) | |
| Missing | 1 (17) | 1 (11) | |
| Mean body mass index (kg/m2) | 25.4 (22‐28.3) | 25.8 (23.3‐25.9) | 0.72 |
| Clinical characteristics | |||
| Duration of Rx (years) | 8.13 (4.8‐10.8) | 8.6 (6.1‐12.78) | 0.91 |
| Rx (%) | 0.46 | ||
| Lamivudine | 3 (50) | 1 (11) | |
| Adefovir | 1 (17) | 3 (33) | |
| Lamivudine and adefovir | 2 (33) | 5 (56) | |
| Alkaline phosphatase (U/L) | 66.7 (51‐102) | 63 (39‐87) | 0.95 |
| ALT (U/L) | 42 (30‐65) | 38 (28‐42) | 0.56 |
| AST U/L) | 23 (8‐33) | 24 (13‐52) | |
| 0.68 | |||
| Total bilirubin (mg/dL) | 0.63 (0.4‐0.8) | 0.58 (0.2‐1) | 0.59 |
| Albumin (g/dL) | 4.3 (4‐4.6) | 4.2 (3.4‐5) | 1.00 |
| International normalized ratio | 1.0 (0.95‐1.2) | 1.0 (0.91‐1.2) | 0.59 |
| Platelets (K/uL) | 202 (116‐228) | 210 (161‐311) | 0.91 |
| HBeAg‐positive at Rx initiation (%) | 2 (33) | 6 (67) | 0.31 |
| Anti‐HBe‐positive (%) | 5 (83) | 6 (67) | 0.6 |
| HBV DNA undetectable | 6 (100) | 8 (89) | |
| qHBsAg (IU/mL) | 296.47 (0.3‐1,036.1) | 1990.7 (71.5‐10,250.9) | 0.04 |
| HBV RNA (log U/mL) | 0.3 (0‐1.7) | 0.9 (0‐2.6) | 0.18 |
| Histology activity index score | 2.2 (1‐5)* | 2.5 (1‐5) † | 0.64 |
| Ishak fibrosis score | 1.0 (0‐2)* | 1.0 (0‐3) † | 0.81 |
*
One patient did not undergo liver biopsy.
†
One patient did not undergo liver biopsy.
Abbreviation: GT, genotype.